Clinical trial
A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and…
NCT00240708 · Janssen Pharmaceutical K.K., Industry · Completed
Key facts
| NCT number | NCT00240708 |
|---|---|
| Title | A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia |
| Official title | A Parallel-Group Comparative Open-Label Study of Long-Acting Injectible Risperidone Versus Risperidone Tablets in Patients With Schizophrenia. |
| Lead sponsor | Janssen Pharmaceutical K.K., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | risperidone |
| Enrollment | 205 |
| Start date | Jun 1, 2004 |
| Completion | Apr 1, 2006 |
| First posted | Oct 18, 2005 |
| Last update posted | May 17, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: